Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Urinary Incontinence
Compound Receives Exemption for Clinical Testing in U.K.
May 6th, 2000
NicOx SA announced that a Clinical Trials Exemption (CTX) for HCT-1026 was approved by the United Kingdom Medicines Control Agency for Phase II clinical testing in urinary incontinence. The CTX gives clearance for a randomized, double-blind, placebo-controlled, crossover clinical trial to be conducted at King's College Hospital in London under the supervision of Prof. Linda Cardozo. The study will evaluate the effect of HCT-1026 in 24 patients with symptoms of urinary frequency and urgency, with or without urinary incontinence (overactive bladder). Phase I clinical studies with HCT-1026 have shown the excellent safety and potent prostaglandin...
Source: Women's Health Weekly (2000-05-06)
|
